099430 — BioPlus Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for BioPlus Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	17,021	24,367	37,418	56,719	65,043
Cost of Revenue
Gross Profit	11,205	16,565	23,646	33,806	39,573
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	10,220	12,039	20,756	31,475	37,008
Operating Profit	6,801	12,327	16,662	25,243	28,035
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	6,719	12,134	14,168	27,471	32,740
Provision for Income Taxes
Net Income After Taxes	5,623	9,703	10,673	20,708	27,422
Minority Interest
Net Income Before Extraordinary Items
Net Income	5,623	9,703	10,673	21,137	25,581
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	5,623	9,703	10,673	21,137	26,258
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	103	174	229	370	433
Dividends per Share